Kate Bingham - Managing Partner

Focus: Biotechnology

Summary:
Kate Bingham joined SVLS in 1991. Kate currently serves or has served on the boards of Affibody, Dynogen, Hexagen, Ingenium, LeukoSite, MedNova, Metris, Nexan, PowderMed, and Trine Pharmaceuticals and has been responsible for investments in Alantos, Auxilium, Genosis, Gyros, Kinetix, KuDOS, Lorantis and Micromet.

Prior Experience:
Prior to joining SVLS, Kate worked in business development for Vertex Pharmaceuticals, a biotechnology company in Cambridge, MA and at Monitor Company, a strategy consulting firm.

Qualifications:
Kate has a masters degree in Biochemistry from Oxford University and graduated from Harvard Business School with an MBA.